assess the factors influencing annual treatment costs. Logistic regression analysis was conducted to assess the association between obesity and related clinical factors. RESULTS: A total of 341 (3.4%) children or adolescents received an obesity diagnosis during the study period. The average annual treatment costs were $7491 (SD ± 8371) for patients experiencing obesity and $5364 (SD ± 15,322) otherwise. A total of 4204 (42.5%) patients received atypical antipsychotics, 2237 (22.6%) with other anticonvulsants, 2237 (22.6%) with lithium, and 3890 (39.5%) with other anticonvulsants. Being obese is associated with atypical antipsychotic use (odds ratio [OR] = 1.49, 95% confidence interval [CI] 1.18–1.88), and key comorbidities like diabetes mellitus (OR = 3.40, 95% CI 1.96–5.89) and hypertension (OR = 4.41, 95% CI 2.70–7.20). Higher treatment cost is associated with the use of atypical antipsychotics (p < 0.0001), hospitalization (p < 0.0001), ER visit (p < 0.0001), and some key comorbidities like diabetes mellitus (p < 0.0001) and substance abuse disorder (p < 0.0001). CONCLUSION: Higher treatment costs are associated with obesity in children or adolescents with bipolar disorder. Metabolic complications should be considered by clinical practitioners when prescribing medication in this population.

PODIUM SESSION II

HEALTH CARE DECISION-MAKER’S CASE STUDIES II

THE IMPACT OF THE PROJECT OF ENHANCING COVERAGE RATE FOR PATIENTS WITH CANCER

Lee SM, Nam MH, Yoon SH, Kim BY, Choi MR, Cho HS, Lee KD
Health Insurance Review & Assessment Services, Seoul, South Korea
Problem or Issue Addressed: Policy makers of Korean government decided to increase the rate of public expenditure on health per total expenditure on health (coverage rate) in the patients with cancer. There had been conflicts between health care providers and decision makers of health insurance in the use of off-label anticancer drug.
Goals: (1) Stepwise increase coverage rate of the patients with cancer; (2) Rational control of off-label drug use related to treatment of cancer including chemotherapeutic drugs and drugs for cancer pain; (3) To control the reimbursement for the patients with cancer in the limited budget allocation.
Results: The total number of patients whose medical fees were claimed by health care provider was 42.8 million in 2005 and it was 43.4 million in 2006 increased by 1.4%. The total number of patients with cancer among them was 670 thousands in 2005 and it was 710 thousands in 2006, increased by 6.0%. The rate of public expenditure on health per total expenditure on health in the patients with cancer increased from 49.6% to 71.0%. The rate of patients taken with anticancer chemotherapy increased from 5.9% to 7.9%. The expected allocated budget was $97 million $ and the actual spending money was $24 million $.

Lessons Learned: The project was performed successfully by evidence based decision making process and reasonable use of off label drug use.

CASE 5

THE CENTER FOR DRUG POLICY: PARTNERS HEALTHCARE

Reddy P1, Yeh Y1, Clapp M2, Churchill W3
1Partners Healthcare, Charlestown, MA, USA; 2Massachusetts General Hospital, Boston, MA, USA; 3Brigham and Women’s Hospital, Boston, MA, USA

Organization: Center for Drug Policy, Partners Healthcare.
Problem or Issue Addressed: The Pharmacy Cost Management Committee of the Partners Healthcare System (PHS), a consortium of seven greater Boston area hospitals, has recognized the need to control the future growth rate of pharmaceuticals by managing the utilization of new, high cost pharmaceutical technologies and learning from best practices across the network and country. The Center for Drug Policy (CDP) was established in August 2007 to provide the analytical resources to support the Pharmacy Directors and multidisciplinary teams of physician and pharmacist content experts in this endeavor.
Goals: The major objectives of the CDP are to forecast and manage the introduction of new, high cost pharmaceutical technologies and to streamline the development and implementation of common guidelines across the network. Additional objectives of the CDP are to 1) identify and coordinate cost savings opportunities, 2) conduct prospective utilization reviews and assessment, 3) share best practices across the network, and 4) benchmark against high performance organizations nationwide.

Outcome items used in the decision: Both process and outcome-related measures will be measured. For process-related measures, the number of the following outputs and select intermediate steps will be assessed quarterly: guidelines (drug/therapeutic class/disease), budget-impact models, guideline dissemination and implementation, and assessment of guideline impact. Outcome-related measures will be assessed at a global level and a project-specific level. At the global level, annual drug purchases, drug cost/case-mix adjusted discharge, and drug cost/case-mix adjusted patient day will be measured quarterly at each hospital. At a project-specific level, outcomes will depend on the pharmaceutical technology but would include clinical (e.g., adherence to guidelines, time to event, complications, etc.) and economic measures (e.g., volume of drug, length of stay, drug purchases, etc.).

Implementation Strategy: To establish the CDP, the CDP leadership met with key stakeholders across the network of hospitals, undertook a targeted literature review of cost management strategies in the hospital setting, and conducted an on-site visit to another hospital’s CDP. Access to and training on key data resources including drug purchasing data, computerized physician order entry, and cost accounting systems was obtained. A database to track emerging drug therapies and tools to assist in project management were created. Internal processes and tools were developed to ensure quality, consistency, and documentation of guideline development. To facilitate sharing best practices across the hospital network, presentation opportunities have been provided at monthly CDP meetings; in addition, a monthly memo summarizing key Pharmacy & Therapeutics Committees activities across the network has been prepared and distributed to Pharmacy leadership. Templates for ongoing internal reporting were also developed.

Results: As the CDP was established in August 2007, data collection is ongoing; an overview of anticipated results is, however,